Written and maintained by CASRAI Editorial Board
Last updated
The GOLD classification for COPD—published annually by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in its Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease—is the international clinical and regulatory standard for confirming airflow limitation, grading spirometric severity (GOLD 1 to GOLD 4), and stratifying patients by symptom burden and exacerbation risk (the GOLD ABE assessment tool). Whereas obstructive airway guidelines for reversible asthma follow the Global Initiative for Asthma (GINA) framework, pulmonologists, hospitalists, and respiratory clinical trialists rely on GOLD criteria alongside the multidimensional Celli BODE Index to guide bronchodilator/inhaled corticosteroid therapy and predict long-term mortality.
How Does the GOLD Spirometric Grading (GOLD 1–4 by Post-Bronchodilator FEV1) Combine with the GOLD ABE Group Assessment?
Under the GOLD diagnostic workflow, a patient with dyspnea, chronic cough, sputum production, or history of risk-factor exposure (tobacco smoke, biomass fuel, occupational particulates, or alpha-1 antitrypsin deficiency) must first undergo post-bronchodilator spirometry (measured 10–15 minutes after 400 mcg of short-acting beta-2 agonist). A post-bronchodilator ratio of FEV1 / FVC < 0.70 confirms persistent airflow limitation.
Once airflow limitation (FEV1/FVC < 0.70) is established, the modern GOLD assessment separates physiological lung function from clinical symptom/exacerbation grouping into two parallel steps:
Step 1: GOLD Spirometric Grades (GOLD 1–4)
Severity of airflow obstruction is graded solely by the patient’s post-bronchodilator Forced Expiratory Volume in 1 second (FEV1 % predicted):
| GOLD Spirometric Grade | Severity Label | Post-Bronchodilator FEV1 (% Predicted, given FEV1/FVC < 0.70) |
|---|---|---|
| GOLD 1 | Mild | FEV1 ≥ 80% predicted |
| GOLD 2 | Moderate | 50% ≤ FEV1 < 80% predicted |
| GOLD 3 | Severe | 30% ≤ FEV1 < 50% predicted |
| GOLD 4 | Very Severe | FEV1 < 30% predicted |
Step 2: Combining Spirometric Grade with the GOLD ABE Assessment Tool
Beginning with the 2023 GOLD Report (Agustí et al., 2023) and maintained in subsequent updates, GOLD replaced its previous four-quadrant ABCD matrix with the GOLD ABE assessment tool. Recognizing that frequent exacerbations drive clinical prognosis and treatment escalation regardless of baseline dyspnea level, GOLD merged legacy Groups C and D into a single high-risk group—Group E (Exacerbators). In clinical documentation, a patient is assigned both a spirometric grade and an ABE letter (for example, GOLD Grade 3, Group E).
What Are the Cutoffs for the mMRC Dyspnea Scale (≥2), CAT Score (≥10), and Exacerbation History in GOLD ABE?
The GOLD ABE assessment tool crosses the patient’s 12-month history of moderate or severe acute exacerbations (vertical axis) against their current symptom burden measured by either the Modified Medical Research Council (mMRC) Dyspnea Scale or the COPD Assessment Test (CAT) (horizontal axis):
1. Symptom Burden Instruments and Cutoffs (mMRC ≥ 2 or CAT ≥ 10)
- Modified Medical Research Council (mMRC) Dyspnea Scale (0 to 4 Points; High Symptom Cutoff ≥ 2):
- mMRC Grade 0: I only get breathless with strenuous exercise.
- mMRC Grade 1: I get short of breath when hurrying on the level or walking up a slight hill.
- mMRC Grade 2 (Threshold): I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking at my own pace on the level.
- mMRC Grade 3: I stop for breath after walking about 100 meters (or after a few minutes) on the level.
- mMRC Grade 4: I am too breathless to leave the house, or I am breathless when dressing or undressing.
- COPD Assessment Test (CAT — 8 Items, 0 to 40 Points; High Symptom Cutoff ≥ 10): Developed by Jones et al. (2009), the CAT evaluates 8 items (cough, phlegm, chest tightness, breathlessness walking uphill/stairs, activity limitation at home, confidence leaving home, sleep quality, and energy) each scored 0 to 5. Because COPD affects more than dyspnea alone, GOLD prefers the comprehensive CAT over mMRC; a CAT score ≥ 10 defines high symptom impact (and its Minimal Clinically Important Difference [MCID] in clinical trials is a 2-point change).
2. The GOLD ABE Matrix and Initial Pharmacological Alignment
| GOLD ABE Group | 12-Month Exacerbation History | Symptom Burden (mMRC & CAT Cutoffs) | GOLD Initial Pharmacotherapy Framework |
|---|---|---|---|
| Group A | 0 or 1 moderate exacerbations (not leading to hospital admission) | mMRC 0–1 AND CAT < 10 | A bronchodilator (short- or long-acting) |
| Group B | 0 or 1 moderate exacerbations (not leading to hospital admission) | mMRC ≥ 2 OR CAT ≥ 10 | Dual long-acting bronchodilator therapy: LABA + LAMA |
| Group E (Exacerbators) |
≥ 2 moderate exacerbations OR ≥ 1 exacerbation leading to hospitalization | Any mMRC (0–4) and Any CAT (0–40) | LABA + LAMA; consider LABA + LAMA + ICS (triple therapy) if blood eosinophils ≥ 300 cells/μL |
How Does the 4-Variable Celli BODE Index (BMI, Obstruction, Dyspnea, Exercise 6MWT) Predict 4-Year COPD Survival?
While FEV1 is essential for diagnosing COPD, isolated spirometry poorly captures the systemic cachexia, skeletal muscle dysfunction, and exercise intolerance that drive COPD mortality. In a landmark 2004 study published in the New England Journal of Medicine (Celli et al., 2004;350(10):1005-1012), investigators validated the BODE Index—a 0 to 10 point multidimensional scoring system integrating four physiological and functional variables:
- B — Body-Mass Index (BMI, kg/m2)
- O — Airflow Obstruction (Post-bronchodilator FEV1 % predicted)
- D — Functional Dyspnea (mMRC Dyspnea Scale, 0–4)
- E — Exercise Capacity (Distance walked on the 6-Minute Walk Test [6MWT] in meters)
Celli BODE Index Scoring Table (0 to 10 Points)
| Variable | 0 Points | 1 Point | 2 Points | 3 Points |
|---|---|---|---|---|
| FEV1 (% of Predicted) | ≥ 65% | 50% to 64% | 36% to 49% | ≤ 35% |
| 6-Minute Walk Distance (6MWD, meters) | ≥ 350 m | 250 to 349 m | 150 to 249 m | ≤ 149 m |
| mMRC Dyspnea Scale (0–4) | mMRC 0 to 1 | mMRC 2 | mMRC 3 | mMRC 4 |
| Body-Mass Index (BMI, kg/m2) | > 21 kg/m2 | ≤ 21 kg/m2 | — | — |
In Celli et al.’s validation cohort, each 1-point increase in the BODE score was associated with a hazard ratio for all-cause death of 1.34 (and 1.62 for respiratory death), with approximate 4-year survival rates stratified by BODE quartile of:
- Quartile 1 (BODE Score 0 to 2): 80% 4-year survival
- Quartile 2 (BODE Score 3 to 4): 67% 4-year survival
- Quartile 3 (BODE Score 5 to 6): 57% 4-year survival
- Quartile 4 (BODE Score 7 to 10): 18% 4-year survival (frequently used as a referral threshold for lung volume reduction surgery or lung transplantation evaluation)
In hospital inpatient workflows and remote physiological monitoring (using a Nonin pulse oximeter and SpO2 Scale 2 hypercapnic targets on the NEWS2 score), combining GOLD ABE status with BODE quartiles allows clinicians to identify high-risk COPD patients before acute hypercapnic respiratory failure occurs.
Frequently Asked Questions
How does the GOLD spirometric grading (GOLD 1–4 by post-bronchodilator FEV1) combine with the GOLD ABE group assessment?
After confirming COPD with a post-bronchodilator FEV1/FVC ratio < 0.70, clinicians assign both a spirometric grade based on FEV1 % predicted—GOLD 1 (≥80%), GOLD 2 (50%–79%), GOLD 3 (30%–49%), or GOLD 4 (<30%)—and a clinical GOLD ABE group based on symptom scores and 12-month exacerbation history. The spirometric grade quantifies physiological airflow obstruction, while the ABE group guides initial bronchodilator and inhaled corticosteroid selection.
What are the cutoffs for the mMRC Dyspnea Scale (≥2), CAT Score (≥10), and exacerbation history in GOLD ABE?
In the GOLD ABE assessment tool, high symptom burden is defined as an mMRC Dyspnea Scale score ≥ 2 (on the 0–4 scale) or a COPD Assessment Test (CAT) score ≥ 10 (on the 0–40 scale). Patients with 0 or 1 moderate exacerbations not requiring hospitalization are placed in Group A (if mMRC 0–1 and CAT < 10) or Group B (if mMRC ≥ 2 or CAT ≥ 10), whereas patients with ≥ 2 moderate exacerbations or ≥ 1 COPD hospitalization in the past year are placed in Group E regardless of symptom score.
How does the 4-variable Celli BODE Index (BMI, Obstruction, Dyspnea, Exercise 6MWT) predict 4-year COPD survival?
The Celli BODE Index (2004) scores four systemic and respiratory parameters—Body-Mass Index (≤21 kg/m2 = 1 point), Airflow Obstruction by FEV1 % predicted (0–3 points), mMRC Dyspnea (0–3 points), and Exercise capacity via 6-Minute Walk Distance (0–3 points)—on a 0 to 10 scale. Higher BODE quartiles strongly predict mortality, with 4-year survival declining from 80% in Quartile 1 (score 0–2) and 67% in Quartile 2 (score 3–4) to 57% in Quartile 3 (score 5–6) and 18% in Quartile 4 (score 7–10).
